Kenya Medical Research Institute

Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda

Retrieved on: 
Thursday, October 19, 2023
Biomedical Advanced Research and Development Authority, Guinea, Makerere University Walter Reed Project, Sabin Vaccine Institute, Vaccine, Family, Human services, Kenya Medical Research Institute, Administration for Strategic Preparedness and Response, Viral hemorrhagic fever, Organization, BARDA, United States Department of Health and Human Services, Research, Volunteering, Administration, Development, Epidemic, Disease, Clinical trial, Blood, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Polio, Marburg virus disease, Medical device, Pharmaceutical industry

WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers received the single-dose vaccine at Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda today.

Key Points: 
  • WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus.
  • “Makerere University Walter Reed Project (MUWRP) is delighted to partner with the Sabin Vaccine Institute to launch the clinical testing for a preventive Marburg vaccine,” says Dr. Mwesigwa.
  • In addition to the current trial in Uganda and Kenya, Sabin plans to conduct a similar Phase 2 clinical trial for Marburg in the U.S.
  • Sabin has also initiated plans for a Phase 2 Sudan ebolavirus vaccine clinical trial in Uganda and Kenya.

KEMRI and NEC Announce Trials on Biometric-based Vaccination Management System for Newborn Children in Kenya

Retrieved on: 
Tuesday, February 7, 2023
Data Management, Technology, University, Education, Biometrics, Hospitals, Children, Baby, Maternity, Clinical Trials, Science, Software, Networks, Consumer, Health, Research, Caregiver, Voice recognition, Human voice, NEC, Life, Hand, Hospital, Kinango, Vaccination, Electricity, Digital technology, Clinical trial, Kenya Medical Research Institute, Telecommunications, Nagasaki University, KEMRI, Death, Pharmaceutical industry, Vaccine

The Kenya Medical Research Institute (KEMRI), NEC Corporation (NEC; TOKYO: 6701) and Nagasaki University have developed a digital biometric-based vaccination management system for newborn children in Kenya.

Key Points: 
  • The Kenya Medical Research Institute (KEMRI), NEC Corporation (NEC; TOKYO: 6701) and Nagasaki University have developed a digital biometric-based vaccination management system for newborn children in Kenya.
  • Validation of this system is taking place through KEMRI with a clinical trial that began in September 2022 at the Kinango Sub-County Hospital in Kwale.
  • The digital system being provided by NEC, a leader in the integration of IT and network technologies, and KEMRI, one of Africa’s leading research Institutions, will effectively and seamlessly manage vaccination history and scheduling using fingerprint identification for newborn children and voice recognition for caregivers.
  • This technology marks the first time that biometric identification is being used at a hospital to identify newborn children at the time of vaccination, including those immediately after delivery (*1).

The European Medicines Agency (EMA) Validated Regulatory Application for Arpraziquantel, a Potential Treatment for Schistosomiasis in Preschool-Aged Children

Retrieved on: 
Monday, January 23, 2023
UNDP, Snail, Human, European Medicines Agency, Health, Tropics, Partnership, Institute for Colored Youth, SCI, PPP, Kenya Medical Research Institute, Disease, Government of Japan, Swiss Tropical and Public Health Institute, Schistosoma mansoni, Death, Parasitism, Schistosoma haematobium, SCI Foundation, Volunteering, Water, Ministry, Vaccine, Anemia, Consortium, Research, Malaria, Global Health Innovative Technology Fund, Taste, EMA, Learning, Drinking water, Skin, Tuberculosis, Praziquantel, Tropical disease, Bill & Melinda Gates Foundation, Bill, United Nations Development Programme, Child, Tropical climate, United Nations, Pharmaceutical industry, Birth control, Merck, Wellcome, Schistosomiasis

Arpraziquantel, developed by the Pediatric Praziquantel Consortium, is a potential new treatment option tailored to improve child health by filling the treatment gap of an estimated 50 million preschool-aged children with schistosomiasis.

Key Points: 
  • Arpraziquantel, developed by the Pediatric Praziquantel Consortium, is a potential new treatment option tailored to improve child health by filling the treatment gap of an estimated 50 million preschool-aged children with schistosomiasis.
  • On behalf of the Pediatric Praziquantel Consortium, Merck submitted the regulatory application for arpraziquantel to the European Medicines Agency (EMA), which validated this application and started the scientific review process in December 2022.
  • Arpraziquantel represents the first investigational drug that has reached the regulatory phase amongst the portfolio of projects supported by GHIT Fund.
  • The drug praziquantel – the current standard treatment developed in the 1970s – is safe, effective and available for school-aged children and adults.

KEMRI and NEC Announce Trials on Biometric-based Vaccination Management System for Newborn Children in Kenya

Retrieved on: 
Tuesday, February 7, 2023
Universal health care, Caregiver, Kinango, Nagasaki University, Hand, NEC, Death, SDG, Human, Child, Telecommunication, Life, Guideline, Hospital, Partnership, Finger, Medicine, Biometrics, KEMRI, COVID-19, Policy, Vaccine, Kenya Medical Research Institute, Mother, Digital technology, Name, Report, Hospital Records, Clinical trial, Mortality, Voice recognition, Electricity, Classification, Vaccination, Sustainable Development Goals, Research, Pharmaceutical industry, Security printing, Residential care

TOKYO, Feb 7, 2023 - (JCN Newswire) - Kenya Medical Research Institute (KEMRI), NEC Corporation (NEC) and Nagasaki University, Japan, have developed a digital biometric-based vaccination management system for newborn children in Kenya.

Key Points: 
  • TOKYO, Feb 7, 2023 - (JCN Newswire) - Kenya Medical Research Institute (KEMRI), NEC Corporation (NEC) and Nagasaki University, Japan, have developed a digital biometric-based vaccination management system for newborn children in Kenya.
  • This technology marks the first time that biometric identification is being used at a hospital to identify newborn children at the time of vaccination, including those immediately after delivery(1).
  • As of November 2022, data from more than 300 caregivers and newborns had been registered, including the vaccination histories of more than 150 newborns.
  • (1) NEC research as of February 7, 2023
    (2) Source: Levels and trends in child mortality, Report 2021, UN-IGME

The 6th Hainan International Health Industry Expo 2022 kicks off in Haikou, China

Retrieved on: 
Tuesday, November 22, 2022
Growth, Conference, Health, World Health Organization, International One Design, Hainan International Convention And Exhibition Center, South Australian Health and Medical Research Institute, Environment, Chinese People's Political Consultative Conference, Kenya Medical Research Institute, Therapy, Neglected tropical diseases, Chinese Academy of Tropical Agricultural Sciences, Climate, Infection, White paper, Alternative medicine, CAS, Wellness, Chinese Academy of Sciences, CPC, Health care, Convention center, CAE, COVID-19, Chinese Academy of Engineering, Medical device, Development, Pharmaceutical industry

HAIKOU, China, Nov. 22, 2022 /PRNewswire/ -- The 6th Hainan International Health Industry Expo 2022 kicks off at the Hainan International Convention and Exhibition Center in Haikou, Hainan province, China recently.

Key Points: 
  • HAIKOU, China, Nov. 22, 2022 /PRNewswire/ -- The 6th Hainan International Health Industry Expo 2022 kicks off at the Hainan International Convention and Exhibition Center in Haikou, Hainan province, China recently.
  • With three theme pavilions: Regional Characteristics, Innovative Drugs and Medical Devices, and Health and Wellness, the 40,000+ square-meter expo attracted over 500 exhibitors, including many leading companies in their respective fields.
  • Founded in 2017, the Hainan International Health Industry Expo has been successfully held for five years in a row.
  • At the China International Healthcare Industry Summit and International One Health Conference, a number of distinguished guests who are committed to the global health industry delivered keynote speeches on multiple key topics, including the development of the Chinese health sector in the post-pandemic era, in addition to engaging in expert talks, experience sharing, industry-focused discussions and resource promotion.

The 6th Hainan International Health Industry Expo 2022 kicks off in Haikou, China

Retrieved on: 
Tuesday, November 22, 2022
Growth, Conference, Health, World Health Organization, International One Design, Hainan International Convention And Exhibition Center, South Australian Health and Medical Research Institute, Environment, Chinese People's Political Consultative Conference, Kenya Medical Research Institute, Therapy, Neglected tropical diseases, Chinese Academy of Tropical Agricultural Sciences, Climate, Infection, White paper, Alternative medicine, CAS, Wellness, Chinese Academy of Sciences, CPC, Health care, Convention center, CAE, COVID-19, Chinese Academy of Engineering, Medical device, Development, Pharmaceutical industry

HAIKOU, China, Nov. 22, 2022 /PRNewswire/ -- The 6th Hainan International Health Industry Expo 2022 kicks off at the Hainan International Convention and Exhibition Center in Haikou, Hainan province, China recently.

Key Points: 
  • HAIKOU, China, Nov. 22, 2022 /PRNewswire/ -- The 6th Hainan International Health Industry Expo 2022 kicks off at the Hainan International Convention and Exhibition Center in Haikou, Hainan province, China recently.
  • With three theme pavilions: Regional Characteristics, Innovative Drugs and Medical Devices, and Health and Wellness, the 40,000+ square-meter expo attracted over 500 exhibitors, including many leading companies in their respective fields.
  • Founded in 2017, the Hainan International Health Industry Expo has been successfully held for five years in a row.
  • At the China International Healthcare Industry Summit and International One Health Conference, a number of distinguished guests who are committed to the global health industry delivered keynote speeches on multiple key topics, including the development of the Chinese health sector in the post-pandemic era, in addition to engaging in expert talks, experience sharing, industry-focused discussions and resource promotion.

McGill Antimicrobial Resistance Centre to tackle one of humanity’s greatest threats

Retrieved on: 
Monday, September 19, 2022
Medical school, Health, Power Corporation of Canada, McGill, Education, COVID-19, Transplant, Hepatitis C, Risk, MI4, Hospital, McGill University Health Centre, Corporation, Faculty, Disinfectant, Kenya Medical Research Institute, Fonds, Life, AMR, Partnership, Patient, MUHC, Public health, Solution, Bacteria, Humanity, McGill University, Glen, Research, GLOBE, Medicine, Research institute, Montreal General Hospital, Antibiotics, Pharmaceutical industry, Vaccine, Infection, Immunity

MONTREAL, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Antimicrobial resistance (AMR) is a global scale threat to human life and economic prosperity.

Key Points: 
  • MONTREAL, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Antimicrobial resistance (AMR) is a global scale threat to human life and economic prosperity.
  • With the launch of the new McGill Antimicrobial Resistance (AMR) Centre, a partnership between McGill University and the Research Institute of the McGill University Health Centre (RI-MUHC), Montreal is becoming a powerhouse in understanding and preventing AMR.
  • The McGill University Health Centre (MUHC) Foundation raises funds to support excellence in patient care, research and teaching at the McGill University Health Centre, one of the top university hospitals in Canada.
  • www.muhcfoundation.com
    The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre.

CFK Africa Hosts One of CDC’s Largest Overseas Population-Based Disease Surveillance Platforms

Retrieved on: 
Wednesday, June 1, 2022
Philanthropy, Health, Infectious Diseases, Foundation, General Health, Research, Science, Global health, Coronavirus, Pneumonia, Typhoid fever, Research, COVID-19, Rotavirus, Organic, Partnership, Policy, Kenya Medical Research Institute, Disease, CDC, CFK, Infection, Prevalence, Public health, KEMRI, Diarrhea, Vaccine

Since 2007, CFK Africa has partnered with the CDC in Kenya to conduct the surveillance activity among approximately 30,000 residents of Kibera, which is one of the largest informal settlements in Africa and located just outside of Nairobi's central business district.

Key Points: 
  • Since 2007, CFK Africa has partnered with the CDC in Kenya to conduct the surveillance activity among approximately 30,000 residents of Kibera, which is one of the largest informal settlements in Africa and located just outside of Nairobi's central business district.
  • The surveillance program focuses on monitoring infectious diseases such as pneumonia, diarrheal and febrile illnesses, as well as Covid-19, which was added during the pandemic.
  • We are also drawing on the data at CFK Africa to inform new interventions and strengthen our existing programming to meet emerging and increasing needs.
  • Over the years, the CDC's PBIDS initiatives have been established around the world and supported new interventions for rotavirus and a pneumococcal conjugate vaccine (PCV10).

Bay Area Health Trust receives Health Canada Interim Order Authorization for McMaster Molecular Medium

Retrieved on: 
Thursday, March 17, 2022
Kenya Medical Research Institute, Business development, Interim order, Red Feather Development Group, Health, Hospital, Saint Joseph's, MMM, Collection, Risk, COVID-19, Minister of Health (Canada), McMaster University, St. Joseph's Healthcare Hamilton, IO, Entrepreneurship, Safety, US Foods, Public Health Ontario, Environment, PCR, Business, Temperature, Hamilton Health Sciences, CEO, Research institute, Renewable energy, Pharmaceutical industry

HAMILTON, ON, March 17, 2022 /CNW/ - Bay Area Health Trust has today announced its receipt of a Health Canada Interim Order (IO) authorization for its McMaster Molecular Medium (MMM).

Key Points: 
  • HAMILTON, ON, March 17, 2022 /CNW/ - Bay Area Health Trust has today announced its receipt of a Health Canada Interim Order (IO) authorization for its McMaster Molecular Medium (MMM).
  • "This announcement is a testament to the capabilities of the commercialization team at Bay Area Health Trust.
  • Bay Area Health Trust is also seeking US Food & Drug Administration authorization to enable broader opportunities within the US market.
  • Operating businesses with the goal of returning value to its beneficiaries, Hamilton Health Sciences, Hamilton Health Sciences Foundation and McMaster University, Bay Area Health Trust promotes entrepreneurship and invests in growth-oriented businesses to support patient care.

Promising COVID-19 Therapeutic Drug to start Phase 3 Clinical Trial in the United States

Retrieved on: 
Monday, November 22, 2021
Patient, Fonds, Dapsone, CEO, Pneumocystis pneumonia, MUHC, McGill University, Safety, Kenya Medical Research Institute, Research institute, Hospital, Health, McGill University Health Centre, Health Canada, Inflammation, Solution, Faculty, Therapy, Institute, Lupus, COVID-19, Research, Montreal General Hospital, GLOBE, Medical school, Malaria, Tablet, Epidemiology, FDA, Mortality, Innovative Medicines Initiative, Infection, Glen, Acute respiratory distress syndrome, Nasal spray, HIV, Pharmaceutical industry

The drug was previously used to treat infectious diseases, including malaria, lupus, Human Immunodeficiency Virus (HIV) and pneumocystis pneumonia.

Key Points: 
  • The drug was previously used to treat infectious diseases, including malaria, lupus, Human Immunodeficiency Virus (HIV) and pneumocystis pneumonia.
  • Upon successful completion of the Phase 3 Clinical Trial, PULM-001 could be procured by governments and distributed through existing, well-established government networks.
  • The Phase 3 Clinical Trial will take place in North Carolina, Washington and Idaho under the sponsorship of Peters Medical Research and Principal Research Solutions.
  • Pulmonem anticipates a US$6 to $8 million financing will be required by early 2022 to complete the Phase 3 Clinical Trial.